NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Centers for Disease Control and Prevention (the “CDC”) reported 105,007 drug overdose deaths – with 90% involving synthetic opioids like fentanyl Mazindol ER potentially offers a non-opioid alternative, addressing the underlying neurochemical imbalances associated with fentanyl addiction….